ACE OncoCast

In this final episode of our podcast exploring the role of immunotherapy in advanced urothelial cancer, Dr Tom Powles and Dr Aristotelis Bamias discuss the treatment options for patients after first-line or maintenance immunotherapy, including second-line immunotherapy and salvage treatment options. 

In this second podcast, Dr Tom Powles and Dr Aristotelis Bamias discuss the role of immunotherapy in the neoadjuvant or adjuvant setting for patients with locally advanced disease, based on the latest data from clinical trials. 

In the first of three podcasts exploring the role of immunotherapy in advanced urothelial cancer, genitourinary cancer experts Dr Tom Powles and Dr Aristotelis Bamias discuss the latest evidence-based treatment strategies for patients with advanced metastatic urothelial cancer. 

In this episode, the experts assess the latest data on targeted therapy for KRAS G12C-mutated NSCLC, including the first phase III data on targeted therapy. Hear expert opinions of how these results may influence clinical practice.  

Recent advances in genomic profiling technology have led to the identification of several rare actionable alterations in advanced NSCLC; targeted therapies for many of these molecular NSCLC subtypes are now available. In this episode, the experts evaluate the latest updates from clinical trials using these agents and the impact on clinical practice. 

In this episode, the experts discuss the latest insights on osimertinib resistance in EGFR-mutated NSCLC and promising new data on targeting MET amplification, one of the most common acquired resistance mechanisms to first-line osimertinib.

In this episode, lung cancer experts discuss the treatment approach for patients with early-stage, resectable NSCLC who  harbor EGFR sensitizing mutations. Listen to the latest clinical trial data on the use of adjuvant targeted therapy for this patient population.

In this episode, experts explore new data related to EGFR TKI resistance, specifically resistance to osimertinib. Listen to our experts evaluating the real-world data on most common resistance mechanisms to osimertinib and emerging strategies to overcome resistance .  

In this episode, our experts discuss current and new strategies for targeting KRAS G12C mutation. Hear about emerging strategies to enhance activity of current treatment options in this molecular subtype. 

In this episode two experts discuss new data presented at WCLC on targeting MET ex14 skipping mutations. Listen to the latest evidence on managing this rare molecular subtype and how these data may impact clinical practice. 

Novel strategies are needed to improve outcomes for patients with LA SCCHN. Enhancing chemoradiation by targeting Inhibitor of Apoptosis Proteins (IAPs) – a class of proteins that regulate apoptosis and modulate immune responses – is currently the most promising strategy, and a phase III clinical trial is underway. Alternative targeted therapies in combination with (chemo)radiation are also being...

Based on improved survival, PD-1 immune checkpoint inhibitors (± chemotherapy) have become the standard of care for patients with recurrent/metastatic SCCHN. However, in patients with locally advanced disease, the results of several clinical trials evaluating the addition of PD-(L)1 inhibitors to conventional chemoradiotherapy have been disappointing. Dr. Ezra Cohen, Dr. Yungan Tao, and Dr. Jonath...

More than half of patients with head and neck cancer present with locally advanced disease, and high-risk patients continue to have a poor prognosis. The treatment of locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) is complex and requires a multidisciplinary team approach. Dr. Jonathan Schoenfeld, Dr. Ezra Cohen, and Dr. Yungan Tao discuss the current treatment strategies...

In our final episode of a series of advanced urothelial case discussions, two experts review the case of a patient with immunotherapy-related adverse events. Listen in to hear about the latest guidelines for the management of immune-related adverse events and how our experts would manage this patient.

In this penultimate episode of our podcast exploring treatment options for patients with advanced urothelial cancer, our experts discuss the latest data on immunotherapy options for cisplatin-ineligible patients. Learn when and how immunotherapy may be an appropriate treatment approach for your patients.

In this episode of our clinical case discussion podcast, experts explore second-line and salvage treatment options for patients with advanced urothelial cancer. Gain up-to-date information on novel treatment options for patients who have progressed after first-line therapy 

 In this episode of a series of podcasts exploring treatment options for patients with advanced urothelial cancer, our experts discuss the options for a patient who has previously undergone surgery, and is ineligible for cisplatin-based treatment. Learn about the latest treatment recommendations and the impact on patient outcomes.  

 In this episode of our podcast series exploring the best treatment strategies for patients with advanced urothelial cancer, our two experts discuss the most appropriate treatment for a patient with locally advanced urothelial cancer. Listen in to hear what therapy the experts would recommend for this patient.  

In this first of a series of advanced urothelial cancer clinical case discussions, two experts discuss the first-line treatment strategy for a newly-diagnosed patient who is eligible for cisplatin-based chemotherapy. Listen in to hear evidence-based views on the best treatment approach for this patient. 

Clinicians face challenging decisions on what treatment strategies to use after progression on combination therapy. Also, adverse event management is an important aspect of patient care. Dr. Manuela Schmidinger and Dr. Bernard Escudier discuss the most effective treatment options in this setting and strategies for managing adverse events. 

Combinations of ICIs or ICIs with TKIs are now part of the first-line treatment strategy, based on the results of phase III trials. The burning question in clinical practice is whether one ICI-based combination is superior to other regimens. Dr. Manuela Schmidinger and Dr. Bernard Escudier discuss these combinations and the optimal sequence of drugs. 

The benefit of adjuvant therapy in preventing or delaying recurrence and improving survival for patients with localized or locally advanced RCC remains debatable. Dr. Manuela Schmidinger and Dr. Bernard Escudier discuss this hot topic. 

 With immunotherapy shifting to the frontline setting, clinicians face challenging decisions on how to treat patients after progression. Novel treatments are being developed with promising data. Dr. Tom Powles and Dr. Joaquim Bellmunt discuss the options available and this exciting area of research.

Several clinical trials are underway to evaluate ICIs in the neoadjuvant setting, and recent data indicate that adjuvant therapy may improve survival in patients with advanced urothelial cancer. Dr. Tom Powles and Dr. Joaquim Bellmunt discuss the latest evidence. 

ICIs have been approved as front-line treatment for certain patient populations, and ICI as maintenance therapy has also been approved. Several randomized phase III trials are underway investigating the use of ICIs in the first-line setting. Dr. Tom Powles and Dr. Joaquim Bellmunt discuss the latest data and how this impacts patient care.